NV-NEVADANANO
NevadaNano, the world’s leading innovator in gas detection sensor technology, announced that Crowcon Detection Instruments Ltd. uses the Molecular Property Spectrometer™ (MPS™) sensors in their new Gasman flammable gas detection products. The new systems allow employees to rely on a single device to identify and alert them to the presence of 19 potentially dangerous gases in their work environment.
“NevadaNano is proud to provide the sensor technology for Crowcon’s ground-breaking Gasman personal monitors," said Ralph Whitten, President, and Member of Board of Directors, at NevadaNano. “Our MPS sensors deliver unprecedented accuracy in detecting multiple flammable gases simultaneously, creating a safer work environment and protecting employees’ health and safety.”
NevadaNano offers a variety of gas detection sensors for flammables, all of which deliver unprecedented reliability and accuracy. Unlike traditional sensors, a single MPS sensor accurately reports 0-100% LEL across 19 flammable gases, including hydrogen, with a single factory calibration and no field maintenance over their lifetime. This capability addresses the need for a flexible sensor platform suitable for complex industrial environments and offers life-saving accuracy in environments with blended combustible gases.
Integrated, real-time measurements and built-in compensation for temperature, pressure, and humidity ensures superb accuracy of the MPS flammable gas sensors. Gas concentration readings are accurate across the wide environmental range, including rapid environmental transients, delivering best-in-class false-positive accuracy. The company’s MPS sensors are inherently immune to drift, decay, or poisoning.
“Our reliable portable gas monitors now have the industry-leading sensor technology that your applications demand. Gasman flammable portable monitors with MPS sensors help reduce fleet maintenance, increase operational up-time, and lowers total cost of ownership,” said Ed Clapham, Portables Product Manager of Crowcon Detection Instruments. “More importantly, the innovative technology provides peace of mind by protecting workers in virtually any multi-gas environment.”
The Gasman with MPS is ATEX Zone 0 approved, allowing operators to enter areas where an explosive gas atmosphere is present continuously or for long periods without concern. In addition, the use of the MPS sensor quadruples the battery life as compared to legacy solutions, protecting workers for more extended periods. In addition, the Gasman with MPS is hydrogen (H2) ready. A single MPS sensor accurately detects hydrogen and common hydrocarbons without recalibration in a fail-safe, poison-resistant solution.
About NevadaNano
NevadaNano's programmable, multi-gas detection technology is the first new approach to flammable gas detection in over 40 years. The MPS technology was developed with the support of DARPA, the DOD, and the Department of Homeland Security for the most challenging gas detection applications and is the winner of the coveted R&D100 award and the Tech Connect National Innovation award. The sensors utilize 24 patented inventions to tackle the toughest chemical analysis tasks. For information visit NevadaNano.com or connect on LinkedIn .
For more information, contact NevadaNano at info@NevadaNano.com or connect on Linkedin . For more on Crowcon, visit www.crowcon.com and connect on Twitter and LinkedIn.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210907005204/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 17:00:00 CET | Press release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release
Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release
- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom